Purinergic P2Y Receptor Antagonists
"Purinergic P2Y Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes.
Descriptor ID |
D058921
|
MeSH Number(s) |
D27.505.519.625.725.400.200.200 D27.505.696.577.725.400.200.200
|
Concept/Terms |
Adenosine Diphosphate Receptor Antagonists- Adenosine Diphosphate Receptor Antagonists
- ADP Receptor Blockers
- Blockers, ADP Receptor
- Receptor Blockers, ADP
- ADP Receptor Antagonists
- Antagonists, ADP Receptor
- Receptor Antagonists, ADP
|
Below are MeSH descriptors whose meaning is more general than "Purinergic P2Y Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Purinergic P2Y Receptor Antagonists".
This graph shows the total number of publications written about "Purinergic P2Y Receptor Antagonists" by people in UAMS Profiles by year, and whether "Purinergic P2Y Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2019 | 1 | 0 | 1 | 2018 | 1 | 0 | 1 | 2014 | 1 | 0 | 1 | 2013 | 1 | 0 | 1 | 2012 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Purinergic P2Y Receptor Antagonists" by people in Profiles over the past ten years.
-
Balanescu DV, Aziz MK, Donisan T, Palaskas N, Lopez-Mattei J, Hassan S, Kim P, Song J, Ntim W, Cilingiroglu M, Marmagkiolis K, Iliescu C. Cancer treatment resumption in patients with new-generation drug-eluting stents. Coron Artery Dis. 2021 Jun 01; 32(4):295-301.
-
Abo-Aly M, George B, Shokri E, Chelvarajan L, El-Helw M, Smyth SS, Abdel-Latif A, Ziada K. Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction. J Thromb Thrombolysis. 2021 Oct; 52(3):934-940.
-
Jain N, Hunt SL, Cui H, Phadnis MA, Mahnken JD, Shireman TI, Dai J, Mehta JL, Rasu RS. Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis. Cardiovasc Drugs Ther. 2019 10; 33(5):511-521.
-
Singh M, Raghavan D, Williams JS, Martin BC, Hudson TJ, Owen RR, Jain N. Prevalence of Chronic Kidney Disease, Thrombotic Cardiovascular Events, and Use of Oral P2Y12 Inhibitors among Veterans. Am J Nephrol. 2018; 47(2):67-71.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|